FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108806933> ?p ?o ?g. }

• W2108806933 endingPage "e81208" @default.
• W2108806933 startingPage "e81208" @default.
• W2108806933 abstract "Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period.FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID).Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia).This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities." @default.
• W2108806933 created "2016-06-24" @default.
• W2108806933 creator A5011711127 @default.
• W2108806933 creator A5017868414 @default.
• W2108806933 creator A5023590716 @default.
• W2108806933 creator A5023766989 @default.
• W2108806933 creator A5028480298 @default.
• W2108806933 creator A5039199295 @default.
• W2108806933 creator A5056254777 @default.
• W2108806933 creator A5063855692 @default.
• W2108806933 creator A5067330259 @default.
• W2108806933 creator A5069397170 @default.
• W2108806933 creator A5070981123 @default.
• W2108806933 date "2013-11-20" @default.
• W2108806933 modified "2023-09-30" @default.
• W2108806933 title "Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe" @default.
• W2108806933 cites W1507718585 @default.
• W2108806933 cites W1516311518 @default.
• W2108806933 cites W1527009493 @default.
• W2108806933 cites W1571310866 @default.
• W2108806933 cites W1604262638 @default.
• W2108806933 cites W1963763403 @default.
• W2108806933 cites W1969164930 @default.
• W2108806933 cites W1980382792 @default.
• W2108806933 cites W1980644144 @default.
• W2108806933 cites W1984235868 @default.
• W2108806933 cites W1990223736 @default.
• W2108806933 cites W1997273588 @default.
• W2108806933 cites W2007113726 @default.
• W2108806933 cites W2008138091 @default.
• W2108806933 cites W2009832071 @default.
• W2108806933 cites W2018167625 @default.
• W2108806933 cites W2018528388 @default.
• W2108806933 cites W2037920209 @default.
• W2108806933 cites W2050747745 @default.
• W2108806933 cites W2054812885 @default.
• W2108806933 cites W2058683641 @default.
• W2108806933 cites W2061394726 @default.
• W2108806933 cites W2061525750 @default.
• W2108806933 cites W2066742955 @default.
• W2108806933 cites W2067376669 @default.
• W2108806933 cites W2067911406 @default.
• W2108806933 cites W2074289946 @default.
• W2108806933 cites W2074324898 @default.
• W2108806933 cites W2077165705 @default.
• W2108806933 cites W2078785409 @default.
• W2108806933 cites W2084769502 @default.
• W2108806933 cites W2086892539 @default.
• W2108806933 cites W2096021509 @default.
• W2108806933 cites W2100004795 @default.
• W2108806933 cites W2113622670 @default.
• W2108806933 cites W2116445878 @default.
• W2108806933 cites W2117979215 @default.
• W2108806933 cites W2136472480 @default.
• W2108806933 cites W2138218422 @default.
• W2108806933 cites W2152770536 @default.
• W2108806933 cites W2157021912 @default.
• W2108806933 cites W2159155203 @default.
• W2108806933 cites W2159666011 @default.
• W2108806933 cites W2162839679 @default.
• W2108806933 cites W2164142166 @default.
• W2108806933 cites W2171104939 @default.
• W2108806933 cites W2171122345 @default.
• W2108806933 cites W2171956687 @default.
• W2108806933 cites W4230556569 @default.
• W2108806933 cites W47623468 @default.
• W2108806933 doi "https://doi.org/10.1371/journal.pone.0081208" @default.
• W2108806933 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3835678" @default.
• W2108806933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24278396" @default.
• W2108806933 hasPublicationYear "2013" @default.
• W2108806933 type Work @default.
• W2108806933 sameAs 2108806933 @default.
• W2108806933 citedByCount "47" @default.
• W2108806933 countsByYear W21088069332014 @default.
• W2108806933 countsByYear W21088069332015 @default.
• W2108806933 countsByYear W21088069332016 @default.
• W2108806933 countsByYear W21088069332017 @default.
• W2108806933 countsByYear W21088069332018 @default.
• W2108806933 countsByYear W21088069332019 @default.
• W2108806933 countsByYear W21088069332020 @default.
• W2108806933 countsByYear W21088069332021 @default.
• W2108806933 countsByYear W21088069332022 @default.
• W2108806933 countsByYear W21088069332023 @default.
• W2108806933 crossrefType "journal-article" @default.
• W2108806933 hasAuthorship W2108806933A5011711127 @default.
• W2108806933 hasAuthorship W2108806933A5017868414 @default.
• W2108806933 hasAuthorship W2108806933A5023590716 @default.
• W2108806933 hasAuthorship W2108806933A5023766989 @default.
• W2108806933 hasAuthorship W2108806933A5028480298 @default.
• W2108806933 hasAuthorship W2108806933A5039199295 @default.
• W2108806933 hasAuthorship W2108806933A5056254777 @default.
• W2108806933 hasAuthorship W2108806933A5063855692 @default.
• W2108806933 hasAuthorship W2108806933A5067330259 @default.
• W2108806933 hasAuthorship W2108806933A5069397170 @default.
• W2108806933 hasAuthorship W2108806933A5070981123 @default.
• W2108806933 hasBestOaLocation W21088069331 @default.
• W2108806933 hasConcept C118552586 @default.
• W2108806933 hasConcept C126322002 @default.

• next